Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.

Ocak I, Bernardo M, Metzger G, Barrett T, Pinto P, Albert PS, Choyke PL.

AJR Am J Roentgenol. 2007 Oct;189(4):849.

PMID:
17885055
2.

Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM.

J Magn Reson Imaging. 1999 Sep;10(3):223-32. Review.

PMID:
10508281
3.

Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer.

Franiel T, Hamm B, Hricak H.

Eur Radiol. 2011 Mar;21(3):616-26. doi: 10.1007/s00330-010-2037-7. Epub 2010 Dec 24. Review.

PMID:
21184082
4.

Multiparametric MRI of solid renal masses: pearls and pitfalls.

Ramamurthy NK, Moosavi B, McInnes MD, Flood TA, Schieda N.

Clin Radiol. 2015 Mar;70(3):304-16. doi: 10.1016/j.crad.2014.10.006. Epub 2014 Dec 1. Review.

PMID:
25472466
5.

Endogenous contrast MRI of cardiac fibrosis: beyond late gadolinium enhancement.

van Oorschot JW, Gho JM, van Hout GP, Froeling M, Jansen Of Lorkeers SJ, Hoefer IE, Doevendans PA, Luijten PR, Chamuleau SA, Zwanenburg JJ.

J Magn Reson Imaging. 2015 May;41(5):1181-9. doi: 10.1002/jmri.24715. Epub 2014 Aug 5. Review.

PMID:
25091144
6.

Magnetic resonance imaging of prostate cancer.

Guneyli S, Erdem CZ, Erdem LO.

Clin Imaging. 2016 Jul-Aug;40(4):601-9. doi: 10.1016/j.clinimag.2016.02.011. Epub 2016 Feb 16. Review.

PMID:
27317204
7.

Prostate Cancer: The Role of Multiparametric Magnetic Resonance Imaging.

Dias JL, Pina JM, João R, Fialho J, Carmo S, Leal C, Bilhim T, Marques RM, Pinheiro LC.

Acta Med Port. 2015 Mar-Apr;28(2):240-9. Epub 2015 May 29. Review.

8.

Nanoparticle-based systems for T(1)-weighted magnetic resonance imaging contrast agents.

Zhu D, Liu F, Ma L, Liu D, Wang Z.

Int J Mol Sci. 2013 May 21;14(5):10591-607. doi: 10.3390/ijms140510591. Review.

9.

Multicentre imaging measurements for oncology and in the brain.

Tofts PS, Collins DJ.

Br J Radiol. 2011 Dec;84 Spec No 2:S213-26. doi: 10.1259/bjr/74316620. Review.

10.

Magnetic resonance imaging for localization of prostate cancer in the setting of biochemical recurrence.

Panebianco V, Barchetti F, Grompone MD, Colarieti A, Salvo V, Cardone G, Catalano C.

Urol Oncol. 2016 Jul;34(7):303-10. doi: 10.1016/j.urolonc.2016.01.004. Epub 2016 Mar 21. Review.

PMID:
27012939
11.

Computer-aided Detection of Prostate Cancer with MRI: Technology and Applications.

Liu L, Tian Z, Zhang Z, Fei B.

Acad Radiol. 2016 Aug;23(8):1024-46. doi: 10.1016/j.acra.2016.03.010. Epub 2016 Apr 25. Review.

PMID:
27133005
12.

Imaging and Markers as Novel Diagnostic Tools in Detecting Insignificant Prostate Cancer: A Critical Overview.

Reva S, Nosov A, Novikov R, Petrov S.

Int Sch Res Notices. 2014 Jul 15;2014:243080. doi: 10.1155/2014/243080. eCollection 2014. Review.

13.

Predictive modeling techniques in prostate cancer.

Tewari A, Porter C, Peabody J, Crawford ED, Demers R, Johnson CC, Wei JT, Divine GW, O'Donnell C, Gamito EJ, Menon M.

Mol Urol. 2001 Winter;5(4):147-52. Review.

PMID:
11790275
Items per page

Supplemental Content

Write to the Help Desk